OOIR: Observatory of International Research

Papers

(The median citation count of JAMA Oncology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Insights Into Immune-Mediated Disease and Cancer Risk—Delivering on the Promise of UK Biobank Big Data	1296
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?	452
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer	450
Information Blocking and Oncology	359
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply	312
JAMA Oncology	260
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma—Is This the New Standard of Care?	259
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants	252
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply	250
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer	238
Overall Survival in the CAIRO5 Clinical Trial	232
Active Cellular Immunotherapy in the Desert of Advanced Prostate Cancer	228
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration	228
The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years	214
Stargazers	212
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen	206
Errors in Key Points and Abstract	195
Error in Text	186
Piercing the Fog	181
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers	180
The Multidisciplinary Cancer Conference	170
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?	169
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab	161
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia	158
Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades	147

Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults	142
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply	141
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention	140
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab	133
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!	130
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors	127
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer	124
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer	124
Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy	122
Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer	120
Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors	118
High-risk Medulloblastoma—Balancing the High Stakes of Molecular Profiling to Enhance Treatment Responsivity	118
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories	117
Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials—Reply	111
The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable	110
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US	109
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?	107
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply	107
Internal Mammary Nodal Irradiation Debate for Node-Positive Breast Cancer—Has the Needle Moved?—Reply	105
Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography—The IP1-PROSTAGRAM Study—Reply	105
Coding Errors in Study of Eligibility for Lung Cancer Screening	103
Is Colorectal Cancer Screening Absolutely Beneficial for Older Adults?	98
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?	96
Errors in Reported Outcomes and Table	96
The SOUND Randomized Clinical Trial Results	95
Results of the TARGET-TP Randomized Clinical Trial	95
Trauma	92
Variability in COVID-19 Vaccine Response Among People With Cancer	92
An Atypical Rash on the Chest	91
JAMA Oncology	91
Immunotherapy Before Chemoradiotherapy—More Is Better?	89
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer	88
The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval	88
Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic	87
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers	84
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent	84
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis	83
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	82
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers—Reply	82
Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic	80
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply	80
Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence	80
Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewind”	79
Accelerated Approval Is Not Conditional Approval	78
Shifting Toward Precision Oncology in SCLC Treatment	78
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy	77
Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size	76
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer	75
Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation	73
Clinical Trial Diversity—Will We Know It When We See It?	73

Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms	73
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 2019	73
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma	72
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia	72
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?	72
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer	71
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma	71
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy	71
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients	71
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Don	70
Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy	70
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer	70
Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set	70
Is the Delphi’s Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?—Reply	69
JAMA Oncology	69
Change of Article Status to Open Access	69
Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China	69
Standardized Definitions for Efficacy End Points for Adjuvant Trials—The Updated STEEP Criteria	69
Does Circulating Tumor DNA Measure Up to Prostate-Specific Antigen?	69
Exposure Histories and Cancer Risk—What Can We Learn?	68
On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer	68
JAMA Oncology Peer Reviewers in 2021	68
Baseline Evaluation of Cancer Mortality in US States that Expanded Medicaid vs Nonexpansion States	67
Methodological Issues in Study of Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes	66
Role of Patient-Reported Outcome Measures in the Inpatient Setting—Reply	65
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer—The A021501 Trial—Reply	65
Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication	65
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	64
Searching Beyond Programmed Cell Death Ligand 1 in Metastatic Breast Cancer—Still Haven’t Found What We’re Looking For	64
Analysis of Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy Using Pooled Trial Data Matched by Propensity Score	63
JAMA Oncology	63
The ORATOR Trials Have Spoken—Where Do We Go From Here?	63
The Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers	62
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL	62
Endocrine Society Hypercalcemia of Malignancy Guidelines	62
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer	62
Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia	61
Challenges in Shared Care Research in Hematopoietic Cell Transplantation—Reply	61
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma	61
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer	60
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer	58
Self-reported Transportation Barriers to Health Care Among US Cancer Survivors	57
Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer	57
“You’ve Got Mail”—Receiving Bad News Through a Patient Portal	57
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma	56
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer	56
Characterizing Lung Cancer in Li-Fraumeni Syndrome	56
Global Stage Distribution of Breast Cancer at Diagnosis	55
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer	55
Treatment of Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens	55
Luminal and Basal Subtypes of Metastatic Prostate Cancer	54
Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials	54
JAMA Oncology	53
Duration and Dose of Adjuvant Zoledronic Acid for Treatment of Early Breast Cancer—Reply	52
Sunsets	52
JAMA Oncology	51
Should DDGP Regimen Be the Standard of Care for Advanced Extranodal NK/T-Cell Lymphoma? The New Staging System Matters	51
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer	51
Single-Dose Radiotherapy for Prostate Cancer—Lessons Learned From Single-Fraction High-Dose-Rate Brachytherapy	51
Oral Mucosal Pigmentation in a Patient With Mycosis Fungoides	50
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer—Reply	50
MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas	49
Public Awareness of the Association Between Alcohol and Cancer in the US	49
Valid Analysis of Brain-Specific Progression-Free Survival	49
Exploration of Clinician Perspectives on Multidisciplinary Tumor Board Function Beyond Clinical Decision-making	49
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction—Reply	49
Managing Cancer Pain in Patients With Opioid Use Disorder or Nonmedical Opioid Use	49
The Oncology Industrial Complex—Community Oncology Must Be Given a Seat at the Table—Reply	48
Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015	48
Artificial Intelligence—From Starting Pilots to Scalable Privilege	47
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer	47
Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural Invasion	47
Smoking Status of the US Cancer Population and a New Perspective From the National Cancer Database	47
Errors in Figures 2 and 3	47
Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma—Renewed Enthusiasm and a Lingering Challenge	46
COVID-19 and Cancer	46
Personalized Radiation Therapy—Spurning the “One Size Fits All” Approach	46
Assessment of Phase 3 Randomized Clinical Trials Including Patients With Leptomeningeal Disease	46
Effect of a Symptom Monitoring Intervention for Patients Hospitalized With Advanced Cancer	46
Management of Down Syndrome–Associated Leukemias	46

Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer	45
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma	45
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation	45
Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer	45
Integrating Community Health Workers Into Care for Patients With Advanced Stages of Cancer—Fragility Index Analysis	44
Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer	44
Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma	44
JAMA Oncology	44
Association of Patient-Reported Outcomes With Subsequent Nonfatal Self-injury After a New Cancer Diagnosis	44
Change of Article Status to Open Access	44
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer	44
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer	44
Is Regional Nodal Radiotherapy Necessary for Patients With cN1 and ypN0 Breast Cancer After Neoadjuvant Chemotherapy?—Reply	43
Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker	43
Advancing Truth in Oncology by Complementing Clinical Trials With Evidence From Clinical Practice	43
Two Hands, One Journey	43
Reporting the Analytical Method Is Essential to Assessing Studies in Which Biomarkers Are a Major Study Objective—Reply	43
Scattered Painful Papulonodules in an Older Woman	43
Increasing the Uptake of Cancer Risk Management Strategies for Women With BRCA1/2 Sequence Variations	43
Dog Aloisanov Helped Diagnose My Cancer	42
The SOUND Randomized Clinical Trial Results—Reply	42
Error in Figure	42
Somebody Else’s Palms	41
The Case for Allowing Proton Beam Therapy on Head and Neck Cooperative Group Studies	41
Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies	40
Cervical Cancer Incidence in the US-Affiliated Pacific Islands	40
Stereotactic Radiosurgery vs Conventional Radiotherapy for Spine Metastases	40
Locally Advanced Relapse May Not Be Equal to Stage 3 Non–Small Cell Lung Cancer	40
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction	39
Error in Figure 1	39
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer	39
Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastoma—A New Standard of Care?—Reply	39
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer	39
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer	39
PARP Inhibitors for Breast Cancer Treatment	39
Postoperative Restrictive Opioid Protocols and Durable Changes in Opioid Prescribing and Chronic Opioid Use	39
Errors in Figure 3	39
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma	39
Financial Toxicity Among Asian American Cancer Survivors	38
Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy	38
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients	38
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer	38
Unintended Consequences of Patient Portal Access	38
Error in Affiliation and Address	37
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021	37
The Urgent Need for Affordability Curricula at US Medical Schools	37
JAMA Oncology	37
An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy	37
A Case of Multiple Hemorrhagic Friable Nodules	37
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases	37
Change to Open Access Status	36
Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer—Reply	36
Racial/Ethnic Differences in the 21-Gene Recurrence Score Assay Among Women With Breast Cancer	36
An Intramedullary Enigma	36
Error in Author Surname	36
Is 2045 Optimistic?—Concerns Regarding Rising Vaccine Hesitancy—Reply	35
Comment on Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer	35
Equity and the JAMA Network	35
Duration and Dose of Adjuvant Zoledronic Acid for Treatment of Early Breast Cancer	35
Implementing Resource-Stratified Guidelines in LMICs—More Issues Than Solutions	35
Error in Abstract	34
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck—Reply	34
Osimertinib in Patients With Non–Small Cell Lung Cancer and Uncommon EGFR Mutations—Chasing Unicorns?	34
Change to Open Access	34
Error in the Additional Contributions Section	34
Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?—Reply	34
Racial Disparities and Survival Outcomes in Breast Cancer—Reply	34
Government Funding for the Development of Enzalutamide	34
Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer	33
Charting the Path to Systemic Therapy De-escalation—Oligometastatic Kidney Cancer as a Paradigm	33
Overall Survival in the CAIRO5 Clinical Trial	33
USPSTF Lung Cancer Screening Guidelines and Disparities in Screening Adherence	33
SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents	33
Long-Term Toxicity of Immune Checkpoint Inhibitors—Time to Widen the Lens	32
A Paradigm Shift Toward Population-Based MRI-Targeted Prostate Cancer Screening	32
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer	32
Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials	32
Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma	32
Reexamining Social Determinants of Health Data Collection in the COVID-19 Era	32
High-Dose Aumolertinib for Untreated EGFR-Variant Non–Small Cell Lung Cancer With Brain Metastases	31
Implementing Smoking Cessation Interventions for Tobacco Users Within Oncology Settings	31
Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2	31
Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors	31
Blood Clots, or Thrombosis, in Patients With Cancer	31
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma	31
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer	30
JAMA Oncology—The Year in Review, 2023	30
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue	30
Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer	30
Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity	30
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation	30
Patient Harassment of Medical Trainees	30
Results of the TARGET-TP Randomized Clinical Trial—Reply	30
Watch and Wait for Near-Complete Responders—A Word of Caution	29
Concerns Remain Regarding the Association of Sitting Time and Physical Activity With Cancer Survivorship	29